UK Government And Industry Still Far Apart In Talks on New Pricing Scheme

While many in the UK government have had warm words to say about a new voluntary drug pricing scheme, the pharmaceutical industry body, the ABPI, suggests that this has not resulted in a willingness to move away from the current pricing scheme, known as VPAS. A substantially reformed approach is a fundamental ask from industry. 

“Notwithstanding apparently strong intent from ministers towards a fundamentally new settlement, the government’s initial position envisaged a substantive continuation of the current scheme for an additional five-year term,” the ABPI says in a letter sent